Working... Menu

Effects Of Ciclesonide And Beclomethasone On Lens Opacification In Adult Subjects With Moderate To Severe Persistent Asthma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00254956
Recruitment Status : Completed
First Posted : November 17, 2005
Last Update Posted : April 8, 2009
Information provided by:

Brief Summary:
The primary objective is to demonstrate the non-inferiority of ciclesonide compared to beclomethasone-HFA in the occurrence of Class 1 lens event for nuclear (NO), cortical (C), or posterior subcapsular (P) lens opacification within 12 months. Secondary objectives are to compare ciclesonide and beclomethasone with respect to class II and class III best corrected visual acuity and intraocular pressure from baseline to 12 months.

Condition or disease Intervention/treatment Phase
Respiratory Tract Diseases Respiratory Hypersensitivity Asthma Drug: ciclesonide (XRP1526) Phase 3

Detailed Description:
This is a multi-center, multinational, active-controlled, double-blind, randomized (1:1) parallel group study of the effects of inhaled ciclesonide HFA-MDI 640 mcg/day and beclomethasone HFA-MDI 640 mcg/day on lens opacification in adult subjects with moderate to severe persistent asthma. The study consists of a 1-14 day screening phase during which subject eligibility will be determined, followed by a 12-month double-blind treatment phase. Lens opacification will be evaluated by slit lamp examination performed after pupillary dilation to at least 6.0 mm before randomization and after 4 months, 8 months, and 12 months of treatment using the LOCS III system for grading lens opacities. Best-corrected visual acuity and intraocular pressure will be measured at each eye examination visit. An Independent Data Monitoring Committee (IDMC) will be constituted to monitor safety throughout the double-blind treatment phase.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1568 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multi-Center, Multinational, Randomized, Double-Blind, Parallel Group Study of the Effects of Ciclesonide Hfa-Mdi 640 μg/Day and Beclomethasone Hfa-Mdi 640 μg/Day on Lens Opacification in Adult Subjects With Moderate to Severe Persistent Asthma
Study Start Date : January 2004
Actual Primary Completion Date : June 2005
Actual Study Completion Date : June 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Primary Outcome Measures :
  1. The primary endpoint is the occurrence of a Class I lens event for nuclear (NO), cortical (C), or posterior subcapsular (P) lens opacification within 12 months.
  2. A Class I lens event is defined as any of the following events in either eye:
  3. - 1.Increase from baseline in LOCS III grade of ≥ 0.5 (NO), ≥ 0.8 (C), or ≥ 0.5 (P)
  4. - 2.Cataract surgery

Secondary Outcome Measures :
  1. - 1.Change from baseline to Month 12 in LOCS III grade for (a) nuclear opalescence, (b) cortical opacity, and (c) posterior subcapsular opacity.
  2. - 2.Occurrence within 12 months in either eye of a Class II lens event: Increase from baseline in LOCS III grade of ≥ 0.9 (NO), ≥ 1.5 (C), or ≥ 0.9 (P), or cataract surgery.
  3. - 3.Occurrence within 12 months in either eye of a Class III lens event: LOCS III grade ≥ 2.0 for any type of opacity (NO, C, or P) and a change in LOCS III grade of ≥ 0.9 for NO, ≥ 1.5 for C, and ≥ 0.9 for P, or cataract surgery.
  4. - 4.Change from baseline to Month 12 in best-corrected visual acuity.
  5. - 5.Change from baseline to Month 12 in intraocular pressure (mm Hg).
  6. Tertiary endpoint:
  7. - Change in post-bronchodilator FEV1 from baseline to Month 12.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males or non-pregnant, non-lactating females 18 years of age and older with a history of moderate to severe persistent asthma for a duration of at least 2 months prior to screening.
  • At screening, FEV1 must be ≥ 40% and ≤ 85% of predicted.
  • Documented use of inhaled corticosteroid therapy at any dose for at least 1 month prior to screening.
  • Able to demonstrate acceptable oral inhaler technique.
  • Non-smoker for at least the past year and less than a 10 pack-year smoking history if previous smoker.
  • Written informed consent agreement.

Exclusion Criteria:

  • History of prior cataract surgery in either eye.
  • Evidence of congenital cortical cataract.
  • Inability to grade nuclear, cortical, or posterior subcapsular opacities in either eye with LOCS III at the baseline slit lamp examination.
  • Inability to dilate pupils to at least 6.0 mm.
  • Nuclear opalescence with a LOCS III grade ≥ 4 in either eye at the baseline slit lamp examination.
  • Cortical lens opacities with a LOCS III grade ≥ 3 in either eye at the baseline slit lamp examination.
  • Posterior subcapsular lens opacities with a LOCS III grade ≥ 2 in either eye at the baseline slit lamp examination.
  • Elevated intraocular pressure requiring treatment
  • Best corrected visual acuity less than 74 letters (equivalent to vision worse than 20/30) in either eye at baseline.
  • Females who are pregnant or lactating or have a positive pregnancy test at Visit 1 (Screening).
  • Have had more than 1 in-patient hospitalization in the past year for asthma exacerbations.
  • Have had more than 2 bursts of oral steroids per year for each of the past 2 years prior to screening.
  • Chronic use of oral, injectable, or topical steroids except for inhaled corticosteroids for any condition. Topical corticosteroids designated as having a mild potency by the Stoughton-Cornell Scale or the European Guideline for levels of corticosteroid activity are allowed (see AppendixG).
  • Any chronic condition that is likely to require treatment with oral or systemic corticosteroids other than asthma (e.g. systemic lupus, inflammatory bowel disease, rheumatoid arthritis).
  • Topical ocular steroid treatment within 3 months prior to screening.
  • Chronic or recurrent inflammatory disease in either eye likely to result in visual abnormalities or require treatment with ocular steroids.
  • History of drug or alcohol abuse.
  • Any clinically significant medical condition that would interfere with the subject's ability to participate in and comply with study protocol.
  • Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study.
  • Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.
  • Hypersensitivity to the investigational products or to drugs with similar chemical structures.
  • Have been treated with any investigational drug/product within 30 days prior to Visit 1 (Screening).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00254956

Layout table for location information
Chilly-Mazarin, France, 91380
Sponsors and Collaborators
Layout table for investigator information
Study Director: ICD CSD Sanofi

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: ICD Study Director, sanofi-aventis Identifier: NCT00254956     History of Changes
Other Study ID Numbers: SFY6160
First Posted: November 17, 2005    Key Record Dates
Last Update Posted: April 8, 2009
Last Verified: April 2009

Keywords provided by Sanofi:
respiratory tract diseases
respiratory hypersensitivity

Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Tract Diseases
Respiratory Hypersensitivity
Bronchial Diseases
Lung Diseases, Obstructive
Lung Diseases
Hypersensitivity, Immediate
Immune System Diseases
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Anti-Allergic Agents